Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

Summary

The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.

Eligibility

Inclusion Criteria:

* ≥ 18 years of age at the time of consent.
* Must be able to speak, read, and understand English.
* Participants diagnosed with NSCLC, and:

  * have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or
  * have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or
  * who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment
* Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments)
* Have completed at least two cycles of immunotherapy.
* Self-reported cancer-related fatigued that impacts daily function.

Exclusion Criteria:

* Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months
* Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible.
* Diagnosis of dementia.
* Anemia Hgb \<10 g/dL.
* Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol).
* Untreated hypothyroidism.
* Symptomatic heart failure.
* Oxygen dependent lung disease.
* Cognitively unable to complete interviews per investigator.

Conditions3

Locations2 sites

Browse More Trials